3 recruiting, 2 completed. 3 Not applicable, 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 3 | Recruiting 3 |
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 2 | Completed 2 |
Follow Myelodysplastic Disorders: new trials by email Literature Review of Myelodysplastic Disorders trials Research Report on Myelodysplastic Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Feasibility of a Multi-omics Platform for Hematological Malignancies Multi-omics analyses, Functional tests - Myeloma Multiple, Chronic Leukemia | Not applicable | Recruiting | Azienda Ospedaliero-Universitaria di Parma | 1040 | 2025-03-31 | 2026-03-03 |
| INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP) Functional tests, Multi-omics analyses, Cytogenetics/ FISH - Acute Leukemia, Multiple Myeloma | Not applicable | Recruiting | Azienda Ospedaliero-Universitaria di Parma | 300 | 2023-05-31 | 2026-02-17 |
| Chemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021) Genetic, molecular and/or omics analyses - Chronic Leukemia, Acute Leukemia | Not applicable | Recruiting | Azienda Ospedaliero-Universitaria di Parma | 250 | 2021-07-28 | 2026-03-03 |
| Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006) Idarubicin, Sorafenib, Ara-C - AML, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 78 | 2007-10-01 | 2018-08-23 |
| Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H FLUDARABINE, CAMPATH 1H, FK50 - Myelodysplastic Disorders, Leukemia | Phase 1 / Phase 2 | Completed | Baylor College of Medicine | 40 | 2000-06-01 | 2020-01-18 |
Lymphoproliferative Disorders (3) · Multiple Myeloma (3) · Myeloproliferative Disorders (3) · Leukemia (2) · Carcinoma, Squamous Cell (1) · Leukemia, Myeloid, Acute (1) · Melanoma (1) · Mesothelioma, Malignant (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Paraproteinemias (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Urinary Bladder Neoplasms (1)
Hematologic Diseases (5) · Hemic and Lymphatic Diseases (5) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphatic Diseases (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Blood Protein Disorders (3) · Bone Marrow Diseases (3) · Cardiovascular Diseases (3) · Hemorrhagic Disorders (3) · Hemostatic Disorders (3) · Neoplasms, Plasma Cell (3) · Vascular Diseases (3) · Paraproteinemias (2)
Alemtuzumab (1) · Cytarabine (1) · Idarubicin (1) · In Situ Hybridization, Fluorescence (1) · Sorafenib (1) · fludarabine (1)
Azienda Ospedaliero-Universitaria di Parma (3) · Baylor College of Medicine (1) · M.D. Anderson Cancer Center (1)
Italy (3) · United States (2)
Farhad Ravandi-Kashani, MD (1) · George Carrum, MD (1)